AstraZeneca makes $2 billion equity investment in Summit Therapeutics via convertible preferred shares

Bitget2026/09/28 21:30

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

AstraZeneca to invest USD 2 billion in Summit Therapeutics via convertible preferred shares in a strategic equity deal.
Investment priced at USD 18.36 per common share equivalent, based on a 5-day VWAP plus 10% premium.
AstraZeneca to buy about 108,955 preferred shares convertible into common stock at a 1:1,000 ratio.
Closing expected by end of this week, subject to customary conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Summit Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260928506972) on September 28, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

AstraZeneca makes $2 billion equity investment in Summit Therapeutics via convertible preferred shares

You may also like

Crypto prices